| Haeden Nicole Waymack, | |
|
3317 N Wimberly Dr, Fayetteville, AR 72703-4056 | |
| (479) 521-2752 | |
| (479) 521-4603 |
| Full Name | Haeden Nicole Waymack |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Location | 3317 N Wimberly Dr, Fayetteville, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255042347 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | PA-1138 (Arkansas) | Secondary |
| 363A00000X | Physician Assistant | PA-1138 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Haeden Nicole Waymack, 3317 N Wimberly Dr, Fayetteville, AR 72703-4056 Ph: (479) 521-2752 | Haeden Nicole Waymack, 3317 N Wimberly Dr, Fayetteville, AR 72703-4056 Ph: (479) 521-2752 |
News Archive
CoreObjects is proud to announce the achievement of the Project Management Institutes "Excellence Award" for their role in helping launch a product that enhances the quality of life for patients suffering from diabetes.
Cord Blood America, Inc. today announced it has achieved AABB accreditation for cell therapy activity associated with cord blood processing, storage and distribution.
Research by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG. Affecting about 20 children in Australia each year, DIPG is a devastating disease with an average survival time of just nine months after diagnosis.
Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, has commenced a clinical study to investigate the use of OCT to diagnose basal cell carcinoma in collaboration with the Melanoma Institute of Australia using Michelson's Diagnostics VivoSight system.
A study in Norway suggests echocardiographic screening in the general public for structural and valvular heart disease was not associated with benefit for reducing the risk of death, myocardial infarction (heart attack) or stroke, according to a report published by JAMA Internal Medicine, a JAMA Network publication.
› Verified 8 days ago